Form 4: Carlsmed CEO Cordonnier Exercises, Sells Shares

Carlsmed CEO Michael Cordonnier executed a cashless exercise of stock options and sold shares to cover costs, while also exercising additional options.

Summary

• Carlsmed CEO, President, and Director Michael Cordonnier engaged in multiple transactions involving the company's common stock and stock options.
• On March 2, 2026, Cordonnier exercised options to acquire 197,855 shares of common stock at an exercise price of $0.335 per share.
• Concurrently, on March 2, 2026, he sold 197,855 shares of common stock at a weighted average price of $13.292 per share, with trades ranging from $13.000 to $14.030. This sale was a cashless exercise to cover the exercise price, withholding tax obligations, and broker fees.
• Following these transactions, Cordonnier's direct beneficial ownership of common stock decreased from 1,554,501 to 1,356,646 shares.
• On March 3, 2026, Cordonnier exercised additional options, acquiring 160,567 shares at $0.335 per share and 33,264 shares at $4.352 per share.
• After all reported transactions, Cordonnier's direct beneficial ownership of common stock stands at 1,550,477 shares.
• The options exercised on March 2, 2026, and 160,567 shares of the options exercised on March 3, 2026, were part of a grant from January 8, 2021, with an exercise price of $0.335 and an expiration date of January 7, 2031.
• The 33,264 shares of options exercised on March 3, 2026, were part of a grant from February 19, 2025, with an exercise price of $4.352 and an expiration date of February 18, 2035.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a sale of shares, it's primarily a cashless exercise for tax purposes, indicating the executive is realizing value from long-held options, which is a positive for the executive and reflects past stock appreciation. The overall beneficial ownership remains substantial.

Positives

• The sale of shares occurred at a significantly higher price ($13.292 weighted average) compared to the exercise price ($0.335 and $4.352), indicating substantial unrealized gains on the vested options.
• The exercise of options demonstrates management's continued engagement with their equity compensation plan.

Negatives

• The sale of 197,855 shares, even if for tax and fee coverage, represents a reduction in direct beneficial ownership of common stock by a key executive.
• The net effect of the transactions on March 2, 2026, was a reduction in direct beneficial ownership by 197,855 shares.

Future Outlook

na

Industry Context

StockSavvy.ai notes that insider transactions, particularly option exercises followed by sales, are common events in the executive compensation landscape. While the sale of shares can sometimes be interpreted negatively, in this case, it appears to be a standard cashless exercise to cover taxes and exercise costs, which is a routine part of managing equity compensation for executives in the medical device or biotech industry, where Carlsmed operates.

Stakeholder Impact

• Shareholders may view the sale as a routine event for tax and cost coverage, rather than a lack of confidence, given the context of a cashless exercise.
• Employees holding similar stock options may see this as an example of how executives monetize their equity compensation.

Key Dates

Recommendation

The filing details routine insider transactions related to equity compensation, specifically the exercise of stock options and a subsequent sale to cover taxes and exercise costs. This type of transaction is generally not indicative of a change in the company's fundamental outlook or the executive's long-term confidence. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Carlsmed, CARL, Michael Cordonnier, SEC Form 4, Insider Trading, Stock Options, Equity Compensation, Share Sale, CEO, Director, President